Across TCGA pan-cancer cohorts, PKHD1L1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PKHD1L1 data layer compared with 24 for mass-spec protein and 11 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PKHD1L1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PKHD1L1 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.
LUAD and LSCC are the cancer types where PKHD1L1 mass-spec protein most reproducibly stratifies survival.